Please login to the form below

Not currently logged in
Email:
Password:

GSK to develop cancer drugs with OncoMed

GSK and US biotech OncoMed partner to discover, develop and market antibody therapeutics to target cancer stem cells

UK pharmaceutical company GlaxoSmithKline (GSK) and US-based biotech OncoMed Pharmaceuticals have partnered to discover, develop and market antibody therapeutics to target cancer stem cells.

Per the agreement, OncoMed could earn milestone payments of up to USD 1.4bn, based on the achievement of specified discovery, development, regulatory and commercial milestones. The biotech will also receive double-digit royalties on all collaboration product sales.

GSK has secured the option to invest in a future initial public offering (IPO) by OncoMed, which focuses on discovery and development of cancer stem cell antibody therapeutics. The move could signal a future acquisition, depending on the success of the collaboration.

GSK also has option to license four OncoMed product candidates directed at multiple cancer stem cell targets.

11th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...